Vaccine Technologies Market Report 2026

Vaccine Technologies Market Overview

• Vaccine Technologies market size has reached to $61.38 billion in 2025 • Expected to grow to $99.04 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Increasing Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Rising Global Travel And Pathogen Spread • Market Trend: Quadrivalent Vaccines Provide Broader Protection Against Flu Strains • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vaccine Technologies Market?

Vaccine technologies refer to the scientific methods and tools used to develop, produce, and deliver vaccines that stimulate the immune system to recognize and fight pathogens such as viruses, bacteria, or other harmful microorganisms. The main purpose of vaccine technologies is to safely induce immunity, preventing illness and controlling the spread of pathogens. The main types of vaccine technologies are recombinant or conjugate or subunit, inactivated, live attenuated, and toxoid. Recombinant or conjugate or subunit vaccines use specific pieces of the virus or bacteria, such as proteins or sugars, instead of the whole germ to safely stimulate the immune system. They are administered through various routes, including parenteral, oral, and nasal delivery, and are intended for both infectious and non-infectious disease indications. Vaccine technologies are suitable for all age groups, including pediatric and adult populations, and are distributed through multiple channels such as hospitals and retail pharmacies, government suppliers, and others.

What Is The Vaccine Technologies Market Growth Forecast?

The vaccine technologies market size is expected to see strong growth in the next few years. It will grow to $99.04 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing investments in next-generation vaccine platforms, rising demand for pandemic preparedness solutions, expansion of adult vaccination programs, growing focus on non-infectious disease vaccines, increasing adoption of digital vaccine tracking systems. Major trends in the forecast period include increasing development of mrna and recombinant vaccines, rising focus on rapid vaccine manufacturing platforms, growing adoption of novel delivery technologies, expansion of global immunization programs, enhanced emphasis on cold chain optimization.

Global Vaccine Technologies Market Segmentation

1) By Type: Recombinant Or Conjugate Or Subunit, Inactivated, Live Attenuated, Toxoid 2) By Route Of Administration: Parenteral, Oral, Nasal 3) By Disease Indication: Infectious Diseases, Non-Infectious Diseases 4) By Age Group: Pediatric, Adults 5) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Distribution Channels Subsegments: 1) By Recombinant Or Conjugate Or Subunit: Protein Subunit Vaccines, Virus-Like Particle (VLP) Vaccines, Glycoconjugate Vaccines, Recombinant Vector Vaccines 2) By Inactivated: Whole-Virus Inactivated Vaccines, Split-Virus Inactivated Vaccines, Purified Inactivated Vaccines 3) By Live Attenuated: Viral Live Attenuated Vaccines, Bacterial Live Attenuated Vaccines 4) By Toxoid: Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines

What Is The Driver Of The Vaccine Technologies Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the vaccine technologies market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person to another. The rising prevalence of infectious diseases is due to increased travel, which facilitates the rapid spread of pathogens across borders. Vaccine technologies aid infectious disease treatment by stimulating targeted immune responses, helping prevent and control infections. They support public health efforts by reducing disease spread and severity, improving overall healthcare outcomes. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the vaccine technologies industry.

Key Players In The Global Vaccine Technologies Market

Major companies operating in the vaccine technologies market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, Sanofi SA, AstraZeneca Plc, GSK Plc, Moderna Inc, CSL Limited, Bharat Biotech International Limited, Bavarian Nordic AS, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd, Emergent BioSolutions Inc, Valneva SE, Novavax Inc, Dynavax Technologies Corporation, CureVac NV, Inovio Pharmaceuticals Inc, Serum Institute Of India Pvt Ltd, BioNTech SE, Panacea Biotec Ltd, Biological E Limited

Global Vaccine Technologies Market Trends and Insights

Major companies operating in the vaccine technologies market are focusing on developing innovative solutions, such as quadrivalent influenza vaccines, to provide broader immunization coverage and minimize the risk of strain mismatch. Quadrivalent influenza vaccines are vaccines formulated to protect against four influenza virus strains, two influenza A and two influenza B viruses, offering broader protection than trivalent vaccines. For instance, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent influenza vaccine. The vaccine offers seasonal protection against four influenza strains, including both influenza A and B types, and is administered as a single-dose intramuscular injection and is suitable for use in both adults and children. It helps reduce the burden of seasonal influenza by offering broader strain coverage compared to traditional trivalent vaccines.

What Are Latest Mergers And Acquisitions In The Vaccine Technologies Market?

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Icosavax Inc. for $1.1 billion. With this acquisition, AstraZeneca aims to enhance its respiratory vaccine portfolio by integrating Icosavax's innovative protein virus-like particle (VLP) platform, which includes the phase III-ready combination vaccine candidate IVX-A12 targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax is a US-based biotechnology company specializing in vaccine technologies, particularly in developing virus-like particle (VLP)-based vaccines for respiratory diseases.

Regional Outlook

North America was the largest region in the vaccine technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vaccine Technologies Market?

The vaccine technologies market consists of revenues earned by entities by providing services such as vaccine research and development, formulation and testing, clinical trials management, regulatory support, manufacturing process optimization, and distribution logistics for vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine technologies market also includes sales of mRNA vaccines, viral vector vaccines, protein subunit vaccines, and related raw materials and reagents used in vaccine development and production. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vaccine Technologies Market Report 2026?

The vaccine technologies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine technologies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.